Gilmore Neil O'Neill - 11 Nov 2026 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

SEC form
4
Accepted by SEC
13 Nov 2026, 16:34:07 UTC
Prior SEC filing
06 Nov 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Gilmore Neil O'Neill filed Form 4 for Editas Medicine, Inc. (EDIT) on 13 Nov 2026.

Key facts

  • This page summarizes Gilmore Neil O'Neill's Form 4 filing for Editas Medicine, Inc. (EDIT).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 13 Nov 2026, 16:34.

Change

  • Previous filing in this sequence was filed on 06 Nov 2026.
  • Current net transaction value: -$51,122.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742084 Primary reporting owner

O'Neill Gilmore Neil

Relationship
CEO, Director

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value
-$51,122
Shares
-21,164
Change %
-7.4%
Price
$2.42
Shares after
265,592
Date
11 Nov 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $2.4150 to $2.4156. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .